Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company focused on leveraging genetics to treat neurological diseases, and its news flow reflects progress across a multi-modality pipeline. Press releases frequently highlight updates in Alzheimer’s disease programs, including the anti-tau antibody VY7523 and the tau silencing gene therapy VY1706, as well as broader work in Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other central nervous system conditions.
News items cover clinical and preclinical data presentations at scientific meetings such as the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) and the American Society of Gene & Cell Therapy (ASGCT) annual meeting. Voyager reports new non-human primate and murine data, details on tau and amyloid targeting strategies, and advances in its TRACER™ AAV capsid discovery platform and next-generation capsids designed for blood-brain barrier penetration and immune evasion.
Investors and followers of VYGR can also expect regular financial and operating updates, typically furnished via Form 8-K, that summarize quarterly collaboration revenue, research and development spending, and cash position, along with commentary on cash runway and partnered program milestones. Additional news addresses collaborations and partnerships, including agreements with Neurocrine Biosciences, Novartis Pharma AG, Alexion, AstraZeneca Rare Disease, and a small molecule collaboration and option agreement with Transition Bio targeting TDP-43 in ALS and frontotemporal dementia.
This news page aggregates Voyager’s corporate announcements, scientific data disclosures, partnership updates, and financial reports, providing a centralized view of developments that may influence the company’s therapeutic pipeline and platform evolution. Readers interested in VYGR stock and the company’s role in genetic medicines for neurological disease can use this feed to follow key milestones and scientific progress over time.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced it will disclose its third-quarter 2022 financial and operational results before the market opens on November 8, 2022. Following the results, a live conference call and webcast will occur at 8:30 a.m. ET to discuss the findings. Interested participants can register for the call to receive dial-in details and access a live webcast on Voyager's investor website. Voyager is focused on next-generation AAV gene therapy, aiming to treat debilitating diseases using its proprietary capsids from the TRACER™ discovery platform.
Voyager Therapeutics (Nasdaq: VYGR) recently announced an employment agreement with a new hire, which includes inducement awards approved by its Compensation Committee. The agreement comprises a non-qualified stock option for 60,000 shares and restricted stock units for 30,000 shares. The stock option has a ten-year term with an exercise price of $6.01 per share and vests over four years. The restricted stock units will vest annually over three years, starting on the first anniversary of the effective date, which is set for January 1, 2023.
Voyager Therapeutics (Nasdaq: VYGR) presented significant findings at the European Society of Gene & Cell Therapy (ESGCT) Congress 2022. The data revealed a novel cell surface receptor that enhances the delivery of Voyager's TRACER AAV capsids across the blood-brain barrier (BBB), showing potential for human translation. Additionally, preclinical results indicate ultra-low dosing might achieve therapeutic effects with reduced toxicity. These advancements could transform CNS drug delivery, underscoring Voyager's commitment to addressing critical neurological disorders.
Voyager Therapeutics announced that Pfizer has exercised an option to license a novel capsid from its TRACER platform, triggering a $10 million payment. This validation could lead to further potential payments totaling up to $290 million, including development and regulatory milestones. The licensed capsid targets a rare neurologic disease and supports Voyager's strategy to enhance its internal pipeline, which includes candidates for Parkinson's and ALS. This collaboration indicates strong progress and potential in the gene therapy sector.
Voyager Therapeutics (Nasdaq: VYGR) will present three posters at the 29th Annual Congress of the European Society of Gene & Cell Therapy from October 11-14, 2022, in Edinburgh, Scotland. The presentations focus on advancements in AAV gene therapy, including an engineered BBB-penetrant capsid family and evaluations of dose-response and production methodologies for AAV-based therapies. These developments may enhance treatment for neurological disorders, showcasing the company's commitment to innovation in gene therapy.
Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming investor conferences. The first is Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, featuring a company presentation at 3:45 p.m. ET. The second event is the Truist Securities Genetic Medicine Summit on October 20, 2022, where Voyager will participate in a CNS panel discussion (not webcast). Interested investors can access the presentation and archived webcasts on Voyager's website for 30 days following the events.
Voyager Therapeutics (Nasdaq: VYGR) announced new employment agreements with Peter Pfreundschuh and another employee, granting them non-qualified stock options and restricted stock units. The stock options consist of 200,000 shares for Pfreundschuh and 76,000 shares for the other employee, both with an exercise price of $6.18 per share. These options will vest over four years, while the restricted stock units will vest annually over three years, starting from the first anniversary of the grant effective date of September 19, 2022.
Voyager Therapeutics announces the appointment of new senior leaders to enhance its focus on CNS diseases. Peter Pfreundschuh joins as CFO, Todd Carter as CSO, and Trista Morrison as SVP of Corporate Affairs, effective September 19, 2022. Pfreundschuh brings over 25 years of finance experience, while Carter has significant expertise in neurology. Morrison will strengthen communications and stakeholder engagement. The company aims to maximize its AAV capsid platform and advance its pipeline addressing critical neurological conditions.
Voyager Therapeutics (Nasdaq: VYGR) has prioritized its therapeutic pipeline focusing on gene therapies for Alzheimer's, GBA1 Parkinson's, and SOD1 ALS, which have efficient paths to human proof of biology. The company reported a net loss of $19.1 million for Q2 2022, an improvement from $30.1 million in Q2 2021, aided by reduced R&D and G&A expenses. Voyager's cash position is strong, with $148.1 million as of June 30, 2022, providing a runway into 2024. Notably, Catherine J. Mackey, Ph.D., has been appointed to the Board of Directors.
Voyager Therapeutics (Nasdaq: VYGR) recently presented data at the Alzheimer’s Association International Conference highlighting novel antibodies that inhibit the spread of pathological tau in rodent models. The research demonstrates that these antibodies, which target specific forms of tau, could advance therapeutic options for tauopathies like Alzheimer's. Notably, vectorized antibody expression showed durability exceeding six months post-administration, with substantial efficacy in reducing tau pathology in mouse models. This research builds on prior findings about the potential of their blood-brain barrier-penetrating AAV capsids.
FAQ
What is the current stock price of Voyager Therapeutics (VYGR)?
What is the market cap of Voyager Therapeutics (VYGR)?
